Inj pegfilgrast ex bio 0.5mg
Products billed under this code include Neulasta.
Payment limit per 0.5 MG, by effective quarter, 1Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Neulasta.
Payment limit per 0.5 MG, by effective quarter, 1Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Neulasta | Amgen Inc | 55513-0099-01 | 8 | $1,609.928 |
| Neulasta | Amgen Inc | 55513-0190-01 | 12 | $2,414.892 |
| Neulasta | Amgen Inc | 55513-0192-01 | 12 | $2,414.892 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $201.241 | +$58.008 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted September 17, 2026 |
| 3Q26 | $143.233 | +$15.854 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted September 15, 2026 |
| 2Q26 | $127.379 | +$4.542 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted September 15, 2026 |
| 1Q26 | $122.837 | +$33.493 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted September 15, 2026 |
| 4Q25 | $89.344 | +$30.945 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted September 8, 2026 |
| 3Q25 | $58.399 | +$38.418 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted March 10, 2026 |
| 2Q25 | $19.981 | $0.00 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted March 10, 2026 |
| 1Q25 | $19.981 | −$11.163 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted December 19, 2025 |
| 4Q24 | $31.144 | −$23.982 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 11, 2025 |
| 3Q24 | $55.126 | −$54.628 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 11, 2025 |
| 2Q24 | $109.754 | +$59.076 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted March 11, 2025 |
| 1Q24 | $50.678 | −$24.27 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted December 19, 2024 |
| 4Q23 | $74.948 | −$10.762 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted October 10, 2024 |
| 3Q23 | $85.71 | −$23.975 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 5, 2024 |
| 2Q23 | $109.685 | −$25.481 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted February 23, 2024 |
| 1Q23 | $135.166 | +$3.752 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted December 6, 2023 |
| 4Q22 | $131.414 | −$24.413 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 22, 2023 |
| 3Q22 | $155.827 | −$11.854 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 9, 2023 |
| 2Q22 | $167.681 | −$14.351 | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted December 14, 2022 |
| 1Q22 | $182.032 | – | 0.5 MG | Inj pegfilgrast ex bio 0.5mg | v1, posted June 8, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.